Index

abdominal obesity, 5
acceptance-based treatments, 224, 225
adaptive thermogenesis, 153
ad libitum weight control, 144
Aerobics Center Longitudinal Study, 128
aetiology
  appetite, 97, 98
  children physical activity
    accelerometry, 279
    adiposity, 282–284
    bidirectional causality, 284–285
    confounder, 278
    energy balance, 278
    energy gap, 278
    heart rate and movement sensing, 279–280
    metabolic energy turnover, 278
    physical activity guidelines, 278
    physical inactivity, 279
    physically active, 278
    questionnaires, 279
    reverse causality, 279, 284–285
    sedentary behaviour, 279
    self-reported physical activity, 277
  copy number variants, 90
  epigenetic modifications, 91, 93
  food intake see food intake
gene–environment interactions, 94
genetic testing in, 94
genetic variation affects, 91–94
hunger, 97, 98
missing heritability, 94
monogenic forms, 87–88
multifactorial/polygenic, 87, 88, 90–92
obesity-linked genetic variants, 94
obesogenic medication see obesogenic medication
physical activity and body weight, 126–127
physical activity guidelines, 129
physical fitness, 128
satiation and satiety, 97, 98
sedentary behaviour, 128–129
syndromic obesity, 88, 90
agouti-related protein, 106
alternate-day fasts, 177, 178
American Association on Intellectual and Developmental Disabilities, 235
American Cancer Society, 60
American College of Rheumatology, 65
American College of Sports Medicine, 212, 213
American Diabetic Association, 44
ANGELO framework, 133
anti-obesity drugs
  Contrave, 189
  diet to support, 190–191
  liraglutide, 189–190
  orlistat, 188–189
  Qsymia, 189
  antipsychotics, 113
  anxiety disorders, 73–74
  appetite, 97, 98, 106, 107
  arcuate nucleus, 106
  atypical antipsychotics, 113
  Australian dietary protein recommendations for adults, 145
  Australian Longitudinal Study on Women’s Health, 127
  Australia’s National Obesity Campaign, 335
Baby Eating Behaviour Questionnaire, 273
baby-led weaning, 272
bacteroides, 119, 120, 123
Banting, 141
Bardet–Biedl syndrome, 88, 90
bariatric surgery
  adjustable gastric band, 205, 206
  body weight loss, 198
  childhood obesity, 318
  costeffective and safe, 193
  criteria for, 203
  duodenal switch, 205, 206
  eating behaviour and lifestyle, 194
  eating disorders, 204
  endoscopic procedures, 194

© 2018 John Wiley & Sons Ltd. Published 2018 by John Wiley & Sons Ltd.
Index

impact on nutrition  
- calcium and vitamin D, 207  
- iron, folate and vitamin B₁₂, 207, 209  
- managing weight regain, 209–210  
- micronutrient supplementation, 207, 208  
- nutritional monitoring, 207, 208  
- protein, 207  
- thiamine, 209  
- vitamins A, E and K, 209  
- zinc, copper and selenium, 209

indications for, 193  
knowledge of, 204

National Weight Control Registry, 248

nutritional assessment, 204

permanent surgical procedure, 194

postoperative dietary intervention, 205

preoperative diet/‘liver shrinking’ diet, 204

procedures, 203

risks and benefits, 195–197

Roux-en-Y gastric bypass, 205, 206

sleeve gastrectomy, 205, 206

Beck Depression Inventory, 322

behavioural therapy, 221–222

Belviq, 318

beta-blockers, 115

biguanides, 317

binge eating disorder  
- characteristics, 79–80  
- definition, 78  
- development and treatment of, 80–82  
- diagnosis of, 78  
- DSM-IV, 78  
- weight status, 79

blood–brain barrier, 106

blood pressure, 51

body dissatisfaction, 81

body mass index (BMI)  
- in adults  
  - advantage of, 3–4  
  - application of, 3  
  - clinical methods, 3, 4  
  - clinical staging., 28  
  - International classifications and sub categories, 24  
  - risks and diseases, 4–5  
  - WHO classification, 3, 4  
- binge eating disorder, 81  
- in childhood, 13, 14, 31–33, 265  
- chronic obstructive pulmonary disease, 67  
- in pregnancy, 20  
- unremitting, 22

brain-derived neurotrophic factor, 91

British Obesity and Metabolic Surgery Society, 207

bulimia nervosa, 80

bupropion, 185

Cancer Society’s Cancer Prevention Study I, 58

cardiovascular disease  
- adipose tissue inflammation, 52  
- body mass index, 49  
- causes of  
  - fat distribution and association, 49–50  
  - visceral fat, 50  
  - free fatty acids, 52  
  - insulin sensitivity/adiponectin, 52  
  - leptin resistance, 52  
- research requirements, 52–53  
- risk factors  
  - changes in risk over time, 50  
  - coagulation and fibrinolysis, 51–52  
  - dyslipidaemia, 51  
  - endothelial dysfunction, 51  
  - heart disease and heart failure, 50  
  - hypertension, 50–51

cardiovascular fitness, 128

Cardiovascular Risk in Young Finns Study, 264

CAROT study, 66

Centre for Maternal and Child Enquiries, 20

Change4Life campaign, 332, 333, 337, 350

Child Eating Behaviour Questionnaire, 273

childhood obesity  
- assessment  
  - anthropometric measurements, 33  
  - body weight, 33  
  - clinical factors, 33–34  
  - medical referral, 34  
- bariatric surgery, 318  
- behavioural interventions  
  - clinical guidelines of, 302  
  - contracting, 303  
  - goal setting, 303  
  - relapse prevention, 303  
  - stimulus control, 303  
  - systematic reviews of, 301–302

Belviq, 318

biguanides, 317

birth to early school age, 18

body mass index standard deviation score, 310, 312

cardiovascular risk factors, 267–268

current eating patterns and behaviours, 290

definition of, 11–12

diagnostic criteria  
- body mass index, 31–33  
- waist measurements, 33

dietary advice, 291–292

diary intake  
- fat and sugar intakes, 289–290  
- portion sizes, 290

eating traits, 273–274

environment–gene interactions  
- copy number variant, 266  
- epigenetics, 266–267  
- monogenic forms, 263–264  
- polymorphisms, 264–266

exposure starts early, 271–272

longer-term adiposity outcomes, 305

mealtime interaction, 274

octreotide, 317–318
Index

357

orlistat, 316–317

pharmacological management

physical activity

in activity levels, 296, 297
definition, 295
energy expenditure, 295–296
exercise recommendations, 297–298
sedentary behaviours, 296, 297
prevalence of
ages and genders, 14–15
global situation, 11
socioeconomic status, 15
in USA and UK, 12–14
prevention of
behaviour change interventions, 346
exercise and health science, 339
organisational, 344
parents, intra-individual interventions, 344–346
physical activity guidelines, 340–341
physical and social environments, 342–343
school policy, 343
sedentary behaviour guidance, 340–341
sedentary time, inter-individual interventions, 344

psychological interventions

behavioural therapy, 302–304
cognitive behavioural therapy, 302, 304
parenting programmes, 302, 304
social cognitive theory, 302, 303
solution-focused therapy, 302, 304

Qsymia, 318

residential programmes

benefits and concerns, 310
follow-up outcomes, 311
non-evidence-based, 312
psychosocial benefits, 311, 312
weight loss, 311, 312
wider health benefits, 311

self-regulation, 274

sibutramine, 318

surgical management of

eligibility criteria, 321
malabsorptive procedures, 323
nutritional assessment, 321–323
nutritional monitoring after surgery, 324, 325
restrictive procedures, 323
weight loss surgery, 320–321
treatment, 34–35

weaning, 272–273

weight loss camps

body mass index-standard deviation score, 312
non-evidence-based, 312
psychosocial benefits, 312
weight loss during, 311–312
weight maintenance, 292

‘Children Eating Well’ programme, 292
cholecystokinin, 107–109
chronic non-communicable diseases, 115
chronic obstructive pulmonary disease, 67–68

Chylomycin formation, 122
cigarette smoking, 4
clozapine, 113
coagulation, 51–52
cocaine-and amphetamine-related transcript, 106

cognitive-behavioural therapy, 74, 81, 222–224
colonisation inhibition, 118
commercial marketing techniques, 350
commercial weight management organisations, 164–166
diet and physical activity behaviours, 173
National Health Service, 170, 172
National Institute for Health and Care Excellence, 169, 175
opportunities for, 174
during pregnancy, 173
quality adjusted life year, 173
Rosemary Conley, 169, 170, 172
Scottish Intercollegiate Guidelines Network, 169
Slimming World, 169, 170, 173
strengths of, 174
threats, 174
weaknesses of, 174
Weight Watchers, 169–172
‘compensation index,’ 274
continuous energy restriction, 59
control energy homeostasis, 106, 107
Copenhagen City Heart Study, 126
copy number variants, 90
Coronary Artery Risk Development in Young Adults, 127
corticosteroids, 115
Counterweight Programme, 256
customer relationship management, 333
CVD see cardiovascular disease

DASET survey, 128
development of cancer

cancer survivors, 60–61
epidemiological evidence, 56–57
insulin and growth factors, 57
raised oestrogens, 57
WCRF recommendations, 60

weight loss

bariatric surgery studies of, 58–59
biomarkers, 59
diet, 59, 60
intervention studies of, 58
observational studies of, 57
physical activity, 59
weight management, 60

Diagnostic and Statistical Manual of Mental Disorders

(DSM-IV), 78

Diagnostic and Therapeutic Criteria Committee of the American
Rheumatism Association, 64
diet-induced thermogenesis, 145–147
Diet Trials study, 172
disinhibition, 101
dyslipidaemia, 51

Early Bird study, 18
eating in the absence of hunger, 274
ecological momentary assessment, 80
ectopic fat deposition, 43
edmonton system, 28
Elimination of Obesity Act, 8
endothelial dysfunction, 51
endothelin, 51
endotoxin, 122
energy-deficit diets, 238
energy expenditure, 295
epigenetics, 87
epilepsy, 113
Epode International Network, 335
Epworth score, 194
European Food Safety Authority, 103, 159
European League Against Rheumatism, 65
European Male Aging Study, 22
European Medicines Agency, 183
exercise-induced energy expenditure, 214–216
fad diets
advantages, 179
alternate-day fasts, 177
classification of, 177–178
definition, 177
disadvantages, 179–181
intermittent fasting, 177
mechanism of action, 178–179
popularity, 177
family-based behavioural treatment, 303
fasting
advantages, 179
alternate-day fasts, 177, 178
disadvantages, 179–181
intermittent fasting, 177
mechanism of action, 178, 179
fasting-induced adipose factor, 122
fat-free mass, 100, 101
fat mass and obesity–associated gene, 91
fibrinolysis, 51–52
‘Fighting Fat, Fighting Fit,’ 336
Firmicutes, 119, 120, 123
‘Fit Futures’ Northern Ireland, 335
Five Areas assessment model, 74, 75
‘Food and Fitness–Promoting Healthy Eating and Physical Activity for Children and Young People in Wales,’ 335
food intake
biology/culture
obesogenic environment, 99
omnivores, 98–99
and energy balance, 99–100
physiological control of
satiety cascade
factors, 102
homeostatic and hedonic aspects, 103–104
satiation and satiety, 102–103
sensory and cognitive processes, 102
tonic and episodic control, 102
Football Fans in Training, 166, 230
formula diets
lean body mass loss, 159–160
low-calorie liquid diets, 157
mechanism of action, 158–159
potential applications, 160–161
very-low-energy diets, 157
weight regain, 159–160
Gammaproteobacteria, 120
gastric bypass, 196
genome-wide association studies, 90–91, 264
ghrelin, 107, 108, 110
Glasgow and Clyde Weight Management Service, 246, 247
glucagon-like peptide-1, 107–110, 184–185
glucosamine-6-phosphate deaminase, 2, 91
group-based interventions
commercial weight management organisations, 165–166
definition, 164
gender, 166
obesity interventions, 165
in obesity management, 166–167
weight management, 165
guanine nucleotide-binding protein, 90
gut microbiome
beneficial function, 118
diet, 118–119
dietary factors, 119
geographical location, 118
metabolic mechanisms
colonial energy harvest, 121–122
gastrointestinal microbiota, 121
host gene function and increased adiposity, 122
pro-inflammatory mechanisms, 122–123
prebiotics, 123
traditional culture techniques, 118
weight loss, 119–120
gut permeability, 122
haplotype blocks, 90
health belief model, 336, 350
health professionals, 339
Health Survey for England, 5, 6, 13
health technology assessment, 256
‘Healthy Dads, Healthy Kids,’ 231
Healthy Eating, Active Living, 334
Healthy Weight, Healthy Lives strategy, 332
high-density lipoprotein, 49
homeostatic regulation, 106, 107
hypertension, 50–51
hypothalamus, 106, 107
Impact of Weight on Quality of Life, 322
insulin, 108
insulin-like growth factor (IGF-1), 57
insulin resistance, 43
insulin therapy, 115
intellectual disabilities
children and adults obesity, 235
definition of, 235
determinants of obesity in dietary habits, 236
environment–living arrangements, 237
gender, 236
 genic syndromes, 237
level of, 237
obesogenic medication, 237
physical activity, 236–237
weight management interventions, adults, 238–239
role of carers, 239–240
Intensive Diet and Exercise for Arthritis, 66
intention-to-treat, 306
intermittent energy restriction, 59
International Obesity Task Force, 12
interpersonal psychotherapy, 81
Iowa Women’s Health Study, 58
Iroquois homeobox protein 3 gene, 91
knee osteoarthritis
American College of Rheumatology, 65
clinical features of, 64, 65
prevalence of, 64
very‐low‐energy diets, 158
Krebs’ cycle, 142
laparoscopic adjustable gastric band, 323
LEARN Program for Weight Management, 189
leptin, 108, 263
leptin–melanocortin pathway, 87–89
leptin receptor, 87–89
Lifestyle Challenge study, 116
lipopolysaccharide, 122
liraglutide, 184, 189–190
lithium, 114
lorcaserin, 184
low-calorie diets, 150–151, 153, 154
low-calorie liquid diets
future research, 160
hospital clinical settings, 160
lean mass losses, 159
liquid skimmed milk, 157
weight loss programmes, 162
low-carbohydrate ketogenic diet, 190
macronutrient composition
carbohydrates
ketogenic diet, 143
low-carbohydrate diet, 141–143
very-low-carbohydrate/ketogenic diets, 142–143
fat intake
fat–obesity hypothesis, 143
low-fat diets, 144
Mediterranean diet, 144–145
proteins
recommendations, 145
benefits, 145
dietary protein intake and satiety, 146
diet-induced thermogenesis, 145–147
effects, 145–146
macrovascular complications, 45
meal replacements
benefits, 151–152
dietary adherence, 152
energy-restricted diets, 150, 151
prescription of low-calorie diets, 150–151
risks, 153–154
solid/liquid products, 150
standard behavioural therapy group, 152
use
before bariatric surgery, 154–155
diabetes, 154
polycystic ovarian syndrome, 155
weight maintenance, 153
meal replacements in children, 292
medium-chain triglyceride, 145
melanocortin 4 receptor, 87–89, 263, 264
MEND programme, 334, 335
metabolic syndrome, 5
Metropolitan Life Insurance Company, 3
microvascular complications, 45
Mifflin–St Jeor equation, 150
Mindful Eating Interventions, 225
Mindfulness-Based Eating Awareness Training, 224
moderate–vigorous intensity physical activity, 279
monogenic forms of obesity, 87–88
motivational interviewing, 302
multidisciplinary team, 203
naltrexone, 185
National Bariatric Surgery Registry, 200, 203
national campaigns, eating behaviour
awareness of, 336
behaviour change, 336–337
in England, 331–335
in Northern Ireland, 335
in Scotland, 334
in Wales, 335
worldwide, 335–336
National Cancer Institute Cohort Consortium, 49
National Child Measurement programme in UK, 18
National Health and Nutrition Examination Survey, 12, 13
National Heart, Lung, and Blood Institute, 222
National Obesity Observatory, 222
National Weight Control Registry, 244–249
bariatric surgery, 248
characteristics of participants in, 244
factors, 247
failure in, 249
liquid formula diet, 248
physical activity, 247
self-monitoring weight in, 245
negative affect regulation model, 80
neuronal growth regulator, 1, 91
neuropeptide Y, 106
NICE (National Institute for Health and Clinical/Care Excellence), 113, 159, 164, 169, 175, 222, 229, 257, 315, 316
night eating syndrome, 80
non-alcoholic fatty liver disease (NAFLD), 41, 43
non-esterified fatty acids, 107
non-exercise activity thermogenesis, 215
nudges, 350, 351
Nurses’ Health Study, 127
Nutrition and Diet Resources UK, 292

 obese normoglycaemic, 43
obesogenic environment, 289
ANGELO framework, 133
comprehensiveness, 135
definition, 132
factors, 134–135
fast-food outlet, 133
lack of variation, 135
macro environments, 133
measurement, 135
mediation and moderation, 135
research designs and analyses, 135
obesogenic medication
chronic long-term conditions, 116
treatment, 116
weight gain drugs, 113–115
octreotide, 317–318
oestradiol, 59
olanzapine, 113
opioid receptor mu-1 gene, 91
orlistat, 183–184, 316–317
orlistat plus a low-fat diet, 190
osteoarthritis
clinical features of, 64, 65
clinical management, 65
diagnostic criteria, 64
in knee, 64
obesity and weight loss, 65–67
prevalence of, 64
symptom of, 64
synovial joint, 64

pain, osteoarthritis, 64
pancreatic polypeptide, 107, 108
partial-meal-replacement, 150
Pediatric Quality of Life Inventory, 322
peer-enhanced adventure therapy, 305
peptide tyrosine tyrosine, 109
peripheral hormones
cholecystokinin, 108–109
insulin, 108
leptin, 108
pancreatic polypeptide, 109
peptide tyrosine tyrosine, 109
pharmaceutical iatrogenesis, 113
pharmacological management of weight loss
anti-obesity drugs
Contrave, 189
diet to support, 190–191
liraglutide, 189–190

orlistat, 188–189
Qsymia, 189
cost-effectiveness of, 185–186
glucagon-like peptide-1 receptor agonists, 184–185
lorcaserin, 184
naltrexone/bupropion, 185
orlistat, 183–184
phentermine/topiramate extended release, 184
phentermine, 184
physical activity
in childhood obesity
accelerometry, 279
in activity levels, 296, 297
adiposity, 282–284
bidirectional causality, 284–285
confounder, 278
definition, 295
energy balance, 278
energy expenditure, 295–296
energy gap, 278
exercise recommendations, 297–298
heart rate and movement sensing, 279–280
metabolic energy turnover, 278
physical activity guidelines, 278
physical inactivity, 279
physically active, 278
questionnaires, 279
reverse causality, 279, 284–285
sedentary behaviour, 279, 296, 297
self-reported physical activity, 277
weight loss
ACSM, 212, 213
biological and behavioural compensatory responses, 214–215
dose–response relationship, 216–217
energy balance impact, 213–214
energy intake effect, 215
health benefits, 216
NEAT, 215
and weight gain, 212–213
young people, 280–282
physical activity energy expenditure, 280
‘Play@home’ campaign, 334
polycystic ovarian syndrome, 155
polygenic aetiology, 87, 88
postural hypotension, 160
Prader–Willi syndrome, 88, 90
prebiotics, 123
prescription medications, 115
Prevotellaceae, 122
proopiomelanocortin, 106, 263
protection motivation theory, 350
Proteobacteria, 119
psychotropic medications, 113
public health initiatives
behavioural change techniques, 350–351
evaluation, 352
intervention level, 351
political/policy arena, 352
population, 351
primary outcome, 352
secondary outcomes, 352
theory and practice base for, 349–350

Qsymia, 189, 318
quality adjusted life year, 173, 185
Questionnaire on Eating and Weight Patterns–Revised, 322

'red flags,' 178
resting energy expenditure, 153
resting metabolic rate, 100, 150
retinopathy, 45
risperidone, 113
Roux-en-Y gastric bypass, 120
satiety cascade, 102
satiety-inducing gut hormones, 108
SCALE Diabetes study, 189
SCALE Maintenance study, 190
SCALE Obesity and Prediabetes study, 189
schizophrenia, 113
Scottish Intercollegiate Guidelines Network, 116, 169, 315, 316
Scottish Professional Football League club, 166
Secretary of State for Health, 8
selective serotonin reuptake inhibitors, 115
SH2B adaptor protein, 1, 90
short-chain fatty acids, 118, 122
short-term satiety signals
cholecystokinin, 108–109
ghrelin, 110
glucagon-like peptide-1, 109–110
pancreatic polypeptide, 109
peptide tyrosine tyrosine, 109
sibutramine, 318
SIGN clinical guideline, 28
single nucleotide polymorphisms, 264
sleep apnoea, 51
sleeve gastrectomy, 197
slimming foods, 292
small nucleolar RNA gene cluster, 90
social cognitive theory, 302, 350
social marketing, 332
socioeconomic status, 15
solution-focused therapy, 302, 303
Sports for Liverpool’s Next Generation, 343
Src homology 2 domain-containing adapter protein, 1, 266
surgical management
childhood obesity
eligibility criteria, 321
malabsorptive procedures, 323
nutritional assessment, 321–323
nutritional monitoring after surgery, 324, 325
restrictive procedures, 323
weight loss surgery, 320–321
of weight loss
‘banded sleeve/bypass,’ 198
bariatric surgery see bariatric surgery
body contouring surgery, 198
challenges and future developments, 198, 200
endoscopic weight loss procedure, 194
gastraplication, 197
long-term follow-up, 198, 199
mini-gastric bypass, 197
patient assessment, 193–194
patient preparation, 194
patient selection, 193
postoperative dietary intervention, 205, 207
preoperative assessment and preparation, 203–205
revisional surgery, 198
selection of, 197
surgical procedures, 194–197
SurgiCal Obesity Treatment Study, 207
Swedish Obesity Subjects, 58
sympathetic function in hypertension, 51

'Take Life On' campaign, 334
theory of planned behaviour, 350
thiazolidinediones, 115
topiramate, 184
total daily energy expenditure, 212–215 transtheoretical model of change, 349
tricyclic antidepressants, 115
'Triple P' parenting programme, 302
type 2 diabetes
complications, 45
diagnosis of, 42
epidemiological evidence, 42–43
ethnicity influence, 44–45
incidence of, 41–42
pathophysiological processes, 41, 43–44
physical activity, 41
prevalence of, 41
risk factor, 42

UK National Institute for Health and Care
Excellence, 157
UK’s Foresight programme, 8
United Kingdom Prevention of Diabetes study, 115
United States Institute of Medicine, 20
US CARDIA study data, 20
US Food and Drug Administration, 183
US Nurses’ Health Study, 58
valproate, 113, 114
venous thromboembolism, 195
Verrucomicrobia, 120
very-low-calorie diets, 150, 151, 154, 248
very-low-energy diets
anecdotal evidence, 158
bariatric surgery, 157
hospital clinical settings, 160
increased fertility, 160
knee osteoarthritis, 158
lean mass losses, 159
obstructive sleep apnoea, 158
randomised controlled trials of, 160
skimmed milk powder, 157
type 2 diabetes, 158
vicious circles, 74, 75
visceral adipose tissue, 50
visceral fat, 50
VO2max, 128
waist circumference, 49
waist-to-hip ratio, 49–50
weight bias, 80
weight gain
physical activity, 126–127
physical fitness, 128
prevention of, 129
sedentary behaviour, 128–129
weight loss
cancer risk reduction
bariatric surgery studies of, 58–59
biomarkers, 59
diet, 59, 60
intervention studies of, 58
observational studies of, 57
physical activity, 59
weight management, 60
in childhood obesity
camps, 311–312
current eating patterns and behaviours, 290
dietary advice, 291–292
dietary intake, 289–290
pharmacological management, 315–318
physical activity, 295–298
residential programmes, 310–312
surgical management of, 320–325
weight maintenance, 292
chronic obstructive pulmonary disease, 67
commercial weight management organisations, 169–175
cost burden, 252–254
fad diets see fad diets
formula diets, 157–162
genetic variation affects, 93–94
group-based interventions, 164–167
intellectual disabilities, 235–240
macronutrient composition see macronutrient composition
meal replacements, 150–155
in men
attitudes, 228
behaviour change, 231
clinical management, 229
commercial weight loss programmes, 231–232
diet and alcohol, 230–231
drug treatment, 232
engaging and motivating men, 229–230
epidemiology of, 228
identifying obesity in, 229
physical activity, 231
sex/profession, 232
social, cultural and environmental influences, 228
social support, 231
in osteoarthritis, 65–67
pharmacological management
anti-obesity drugs, 188–191
cost-effectiveness of, 185–186
glucagon-like peptide-1 receptor agonists, 184–185
lorcaserin, 184
naftrexone/bupropion, 185
orlistat, 183–184
phentermine/topiramate extended release, 184
physical activity, 212–218
psychological interventions for
behavioural therapy, 221–222, 225
cognitive therapy/cognitive behavioural therapy, 222–225
mindfulness-based interventions, 224–225
surgical management
‘banded sleeve/bypass,’ 198
bariatric surgery see bariatric surgery
body contouring surgery, 198
challenges and future developments, 198, 200
endoscopic weight loss procedure, 194
gastroplication, 197
long-term follow-up, 198, 199
mini-gastric bypass, 197
patient assessment, 193–194
patient preparation, 194
patient selection, 193
postoperative dietary intervention, 205, 207
preoperative assessment and preparation, 203–205
revisiional surgery, 198
selection of, 197
surgical procedures, 194–197
weight maintenance
after liquid diet, 248
after pharmacological intervention, 247–248
after surgical intervention, 248–249
after very-low-calorie diets, 248
definitions of, 242, 243
extended care, 244–245
Glasgow and Clyde Weight Management Service, 246, 247
health benefits of, 242
National Weight Control Registry, 244, 245
role of physical activity in, 247
unsuccessful weight maintenance, 249
Weight Loss Maintenance Randomised Controlled Trial, 244–245
weight management interventions
cost-effectiveness, 254–257
trial-based economic evaluations, 256
Weight Loss Maintenance Randomised Controlled Trial, 244–247, 249
Wernicke’s encephalopathy, 209
white adipose tissue, 120
Women’s Health Initiative, 58
Women’s Health Study, 127
Women’s Healthy Eating and Living trial, 58
Women’s Intervention Nutrition Study, 58
World Cancer Research Fund, 56, 60
ziprasidone, 113
z-scores, 32–33